Greenlight Capital Gain Therapeutics Inc transactions over time
GANX
Gain Therapeutics Inc historical holders
total: 1
Transactions details
- Total transactions:
- 3
- New positions:
- 1
- Added:
- 1
- Reduced:
- 1
- Held for:
- 0 quarters
- Latest activity:
- 2024 Q1
David Einhorn has been an institutional investor in Gain Therapeutics Inc (GANX) since 2021 Q1. According to 2026 Q3 report, David Einhorn holds 566,130 shares with a market value of roughly $979.40K representing 0.03% of their equity portfolio. The fund/company first acquired GANX in 2021 Q1, initially purchasing 546,560 shares. Since the initial investment, Greenlight Capital has made 2 more transactions in this position.
Does David Einhorn still hold GANX?
Yes, David Einhorn continues to hold Gain Therapeutics Inc (GANX). According to their 2026 Q3 report, they maintain a position of 566,130 shares valued at approximately $979.40K, representing 0.03% of their equity portfolio.
When did David Einhorn first invest in GANX?
David Einhorn first invested in Gain Therapeutics Inc (GANX) in 2021 Q1 at the reported quarter-end price of $14.92 per share, acquiring 546,560 shares in their initial purchase.
GANX transactions history by Greenlight Capital
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q1
|
0.10%
|
566,130
|
$3.77
|
$2,134,310
|
-3.79% (-22,280)
|
-0%
|
|
2023 Q3
|
0.11%
|
588,410
|
$3.28
|
$1,929,985
|
+7.66% (+41,850)
|
+0.01%
|
|
2021 Q1
|
0.57%
|
546,560
|
$14.92
|
$8,155,000
|
new
|
+0.57%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.